FRANKLIN, Tenn. - Acadia Healthcare (NASDAQ:ACHC) Company, Inc. (NASDAQ: ACHC) announced today the appointment of Dr. Stephanie Eken as the company's new Chief Medical Officer. Dr. Eken, a psychiatrist, brings over twenty years of experience in behavioral health to her new role at Acadia, which operates over 250 facilities across 38 states and Puerto Rico.
Dr. Eken will be responsible for leading Acadia's clinical strategy and ensuring that the company's culture and standards of excellence are consistently applied throughout its continuum of care. She will also participate in guiding the business direction by integrating her clinical expertise into key decision-making processes as part of the executive leadership team.
Previously, Dr. Eken served as Chief Medical Officer at Rogers (NYSE:ROG) Behavioral Health, where she was involved in patient care, quality, and facilities expansion. Her background includes a focus on child and adolescent psychiatry, where she developed treatments in specialty programs.
Dr. Eken is taking over from Dr. Michael Genovese, who has been with Acadia for a decade, serving seven years as chief medical officer. Dr. Genovese will continue in a consulting capacity to support a smooth transition.
Chris Hunter, CEO of Acadia Healthcare, expressed his confidence in Dr. Eken's ability to lead the clinical strategy and praised Dr. Genovese for his significant contributions to the company's clinical programs and operational processes.
Acadia Healthcare is the largest stand-alone behavioral healthcare company in the U.S., with a network of 253 behavioral healthcare facilities, approximately 11,200 beds, and about 23,500 employees serving over 75,000 patients daily.
The information in this article is based on a press release statement from Acadia Healthcare Company, Inc.
InvestingPro Insights
As Acadia Healthcare Company, Inc. (NASDAQ: ACHC) welcomes Dr. Stephanie Eken as its new chief medical officer, the company's financial health and market performance remain key factors for investors. According to the latest metrics from InvestingPro, Acadia Healthcare boasts a Market Cap of approximately 7 billion USD, reflecting its significant presence in the behavioral healthcare sector. The company's revenue has shown robust growth over the last twelve months as of Q4 2023, with a 12.2% increase, indicating a strong operational performance.
InvestingPro Tips suggest that while Acadia Healthcare has not been profitable over the last twelve months, analysts predict the company will turn profitable this year. This anticipated profitability, combined with a strong return over the last five years, presents a potentially optimistic outlook for investors. However, with six analysts having revised their earnings downwards for the upcoming period, it's clear that close monitoring of the company's financials will be crucial.
For investors seeking to delve deeper into Acadia Healthcare's financials and performance, there are additional InvestingPro Tips available, offering comprehensive analysis and forward-looking insights. Use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, and unlock access to the full spectrum of tips that could help inform your investment decisions.
With a P/E Ratio (Adjusted) for the last twelve months as of Q4 2023 at 16.41 and a PEG Ratio of 2.99, Acadia's stock valuation metrics are noteworthy. Investors should also be aware that the company does not currently pay a dividend, which may influence investment strategies focused on income generation.
Overall, as Dr. Eken steps into her new role and Acadia Healthcare continues to expand its operations, the company's financial health and stock performance will be areas to watch closely. For those looking to stay ahead, the additional InvestingPro Tips available could provide valuable guidance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.